When choosing between sacituzumab govitecan (SG) and datopotamab deruxtecan (Datto-DXd), oncologists prioritize the differing side effect profiles (diarrhea/neutropenia vs. stomatitis/ocular) and administration schedules (weekly infusions vs. every three weeks) to match patient lifestyle and comorbidities, rather than focusing solely on efficacy.
Despite label warnings against rechallenging trastuzumab deruxtecan (TDXD) after any symptomatic (Grade 2+) interstitial lung disease (ILD), some experts differentiate. For 'soft call' cases with minimal symptoms, they may consider restarting after a transparent patient discussion, believing not all Grade 2 ILDs carry the same risk.
A key debate in early HER2+ breast cancer is whether to use TDXD neoadjuvantly (DESTINY-Breast11) or reserve it for post-op residual disease (DESTINY-Breast05). Many experts favor the neoadjuvant approach to maximize the chance of a pathologic complete response (pCR), which allows for surgical de-escalation and is associated with better outcomes.
To combat payload-related resistance, clinicians are reluctant to use two ADCs with the same payload (e.g., a deruxtecan) consecutively. The preferred strategy is to 'sandwich' a different class of chemotherapy between the two ADCs, hoping to restore sensitivity to the payload.
There is no consensus on managing a patient with stable HR+ disease on endocrine therapy who develops an isolated, treatable brain metastasis. While some oncologists would switch to a CNS-active systemic therapy like TDXD, others advocate for continuing the effective endocrine therapy while managing the brain met locally.
A unique advantage of the ADC datopotamab deruxtecan is its non-myelosuppressive profile. This makes it an especially attractive option for patients whose bone marrow is compromised or 'tired' after receiving intensive prior chemotherapy, a common real-world clinical scenario not always captured in trials.
To manage the high risk of neutropenia with sacituzumab govitecan, prophylactic growth factor (G-CSF) use is becoming standard clinical practice. This is particularly true after the Day 8 administration. For some populations, like Asian patients, it is considered mandatory from the start, sometimes with a dose reduction.
The rationale for combining ADCs with checkpoint inhibitors extends beyond additive effects. Preclinical data shows ADCs can increase T-cell infiltration into the tumor, potentially turning immunologically 'cold' tumors 'hot.' This offers a promising synergistic strategy, especially for PD-L1 negative patients who typically don't respond to immunotherapy alone.
The clinical strategy of 'saving' the most effective drugs for later lines of therapy may be flawed. Data indicates that 20-30% of patients with metastatic breast cancer do not go on to receive a subsequent line of treatment after progression, arguing for the use of optimal therapies like ADCs earlier in the disease course.
Nausea with TDXD is severe enough that the drug is now considered highly emetogenic. The standard of care is a prophylactic three-drug antiemetic regimen (NK1 antagonist, 5HT3 antagonist, and dexamethasone). Waiting for nausea to occur before treating is a clinical error; prevention is paramount.
Patient adherence to prophylactic steroid mouthwash is the critical factor in preventing severe stomatitis from datopotamab. Clinicians find that the most severe cases occur in patients who stop the rinse prematurely because they feel fine, highlighting the need for firm and continuous patient education on this non-negotiable preventive measure.
A defining characteristic of antibody-drug conjugates is not just their response rate, but their remarkable duration of response. Patients who respond often maintain that response for a significantly longer period than with standard chemotherapy, a benefit likely attributable to the ADC's effect on the tumor microenvironment.
For elderly patients with locally advanced cancer who are not candidates for surgery, an ADC with an every-three-week schedule, like datopotamab, can provide an excellent balance of efficacy and tolerability. This approach can achieve local disease control and maintain quality of life, with dose and schedule modifications further improving safety.